Epigallocatechin gallate (EGCG) attenuates severe acute respiratory coronavirus disease 2 (SARS-CoV-2) infection by blocking the interaction of SARS-CoV-2 spike protein receptor-binding domain to human angiotensin-converting enzyme 2.
Ohishi T, Hishiki T, Baig MS, Rajpoot S, Saqib U, Takasaki T, Hara Y.